Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cardiovascular Diabetology
Published in: Cardiovascular Diabetology 1/2023

Open Access 01-12-2023 | Heart Failure | Research

Relationship between cumulative exposure to triglyceride-glucose index and heart failure: a prospective cohort study

Authors: Huancong Zheng, Guanzhi Chen, Kuangyi Wu, Weiqiang Wu, Zegui Huang, Xianxuan Wang, Zekai Chen, Zefeng Cai, Zhiwei Cai, Yulong Lan, Shouling Wu, Youren Chen

Published in: Cardiovascular Diabetology | Issue 1/2023

Login to get access

Abstract

Background

High triglyceride-glucose index (TyG) is a major risk factor for heart failure, but the long-term effect of high TyG index on the risk of developing heart failure remains unclear. Therefore, we aimed to determine the relationship between the cumulative exposure to TyG index and the risk of heart failure.

Methods

A total of 56,149 participants from the Kailuan Study, who participated in three consecutive health examinations in 2006, 2008, and 2010 and had no history of heart failure or cancer were recruited for this study. The cumulative TyG index was calculated as the weighted sum (value × time) of the mean TyG index for each time interval. The participants were placed into quartiles based on their cumulative TyG index. The study ended on December 31, 2020, and the primary outcome was new-onset heart failure during the follow-up period. In addition, a Cox proportional hazards regression model and a restricted cubic spline analysis were used to further evaluate the relationship between cumulative TyG index and the risk of heart failure.

Results

During a median follow-up period of 10.04 years, a total of 1,312 new heart failure events occurred. After adjustment for potential confounding factors, the Cox regression analysis showed that the hazard ratios (95% confidence intervals) for the risk of heart failure in the Q2, Q3, and Q4 groups were 1.02 (0.83,1.25), 1.29 (1.07,1.56) and 1.40 (1.15,1.71), respectively, vs. the Q1 group. The subgroup analysis showed a significant interaction between cumulative TyG index and BMI or waist circumference, but there was no interaction between age, sex and cumulative TyG index. The restricted cubic spline analysis showed a dose-response relationship between cumulative TyG index and the risk of heart failure. In addition, the sensitivity analysis generated results that were consistent with the primary results.

Conclusions

High cumulative TyG index is associated with a higher risk of heart failure. Thus, the TyG index may be useful for the identification of individuals at high risk of heart failure. The present findings emphasize the importance of the long-term monitoring of the TyG index in clinical practice.
Appendix
Available only for authorised users
Literature
1.
2.
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–726.PubMed
3.
Bragazzi NL, Zhong W, Shu J, Abu Much A, Lotan D, Grupper A, Younis A, Dai H. Burden of heart failure and underlying causes in 195 countries and territories from 1990 to 2017. Eur J Prev Cardiol. 2021;28(15):1682–90.PubMed
4.
Wang H, Chai K, Du M, Wang S, Cai JP, Li Y, Zeng P, Zhu W, Zhan S, Yang J. Prevalence and incidence of heart failure among urban patients in China: A National Population-Based analysis. Circ Heart Fail. 2021;14(10):e008406.PubMed
5.
Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD, Finkelstein EA, Hong Y, Johnston SC, Khera A, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011;123(8):933–44.PubMed
6.
Gerich JE. Contributions of insulin-resistance and insulin-secretory defects to the pathogenesis of type 2 diabetes mellitus. Mayo Clin Proc. 2003;78(4):447–56.PubMed
7.
Laakso M, Kuusisto J. Insulin resistance and hyperglycaemia in cardiovascular disease development. Nat Rev Endocrinol. 2014;10(5):293–302.PubMed
8.
Hanley AJ, Williams K, Stern MP, Haffner SM. Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study. Diabetes Care. 2002;25(7):1177–84.PubMed
9.
DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979;237(3):E214–223.PubMed
10.
Muniyappa R, Lee S, Chen H, Quon MJ. Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab. 2008;294(1):E15–26.PubMed
11.
Simental-Mendía LE, Rodríguez-Morán M, Guerrero-Romero F. The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. Metab Syndr Relat Disord. 2008;6(4):299–304.PubMed
12.
Abbasi F, Reaven GM. Comparison of two methods using plasma triglyceride concentration as a surrogate estimate of insulin action in nondiabetic subjects: triglycerides × glucose versus triglyceride/high-density lipoprotein cholesterol. Metabolism. 2011;60(12):1673–6.CrossRefPubMed
13.
Zhao Y, Sun H, Zhang W, Xi Y, Shi X, Yang Y, Lu J, Zhang M, Sun L, Hu D. Elevated triglyceride-glucose index predicts risk of incident ischaemic stroke: the rural chinese cohort study. Diabetes Metab. 2021;47(4):101246.PubMed
14.
Tian X, Zuo Y, Chen S, Liu Q, Tao B, Wu S, Wang A. Triglyceride-glucose index is associated with the risk of myocardial infarction: an 11-year prospective study in the Kailuan cohort. Cardiovasc Diabetol. 2021;20(1):19.PubMedPubMedCentral
15.
Wu S, Xu L, Wu M, Chen S, Wang Y, Tian Y. Association between triglyceride-glucose index and risk of arterial stiffness: a cohort study. Cardiovasc Diabetol. 2021;20(1):146.PubMedPubMedCentral
16.
Guo W, Zhao L, Mo F, Peng C, Li L, Xu Y, Guo W, Sun A, Yan H, Wang L. The prognostic value of the triglyceride glucose index in patients with chronic heart failure and type 2 diabetes: a retrospective cohort study. Diabetes Res Clin Pract. 2021;177:108786.PubMed
17.
Huang Z, Chen Z, Wang X, Ding X, Cai Z, Li W, Cai Z, Lan Y, Chen G, Fang W, et al. Association of Cardiovascular Health score trajectory with Incident Myocardial Infarction in Hypertensive Patients. Hypertension. 2022;79(11):2622–30.
18.
Huang Z, Ding X, Yue Q, Wang X, Chen Z, Cai Z, Li W, Cai Z, Chen G, Lan Y, et al. Triglyceride-glucose index trajectory and stroke incidence in patients with hypertension: a prospective cohort study. Cardiovasc Diabetol. 2022;21(1):141.PubMedPubMedCentral
19.
Wang L, Lee Y, Wu Y, Zhang X, Jin C, Huang Z, Wang Y, Wang Z, Kris-Etherton P, Wu S, et al. A prospective study of waist circumference trajectories and incident cardiovascular disease in China: the Kailuan Cohort Study. Am J Clin Nutr. 2021;113(2):338–47.PubMed
20.
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, et al. The Seventh Report of the Joint National Committee on Prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003;289(19):2560–72.PubMed
21.
Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, Kitzmiller J, Knowler WC, Lebovitz H, Lernmark A, et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003;26(11):3160–7.
22.
Alberti KG, Zimmet P, Shaw J. The metabolic syndrome–a new worldwide definition. Lancet. 2005;366(9491):1059–62.PubMed
23.
Ma C, Gurol ME, Huang Z, Lichtenstein AH, Wang X, Wang Y, Neumann S, Wu S, Gao X. Low-density lipoprotein cholesterol and risk of intracerebral hemorrhage: a prospective study. Neurology. 2019;93(5):e445–57.PubMedPubMedCentral
24.
Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12.PubMedPubMedCentral
25.
Ramdas Nayak VK, Satheesh P, Shenoy MT, Kalra S. Triglyceride glucose (TyG) index: a surrogate biomarker of insulin resistance. J Pak Med Assoc. 2022;72(5):986–8.PubMed
26.
Liu S, Zhao D, Wang M, Qi Y, Sun JY, Liu J, Li Y, Liu J. Association between cumulative blood pressure and long-term risk of cardiovascular disease: findings from the 26-year chinese multi-provincial cohort Study-Beijing Project. Chin Med J (Engl). 2021;134(8):920–6.PubMed
27.
Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, Tavazzi L, Smiseth OA, Gavazzi A, Haverich A, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the Task Force for the diagnosis and treatment of Chronic Heart failure of the European Society of Cardiology. Eur Heart J. 2005;26(11):1115–40.PubMed
28.
Lin YP, Hsu YC, Tsai KZ, Kwon Y, Lin GM. Insulin resistance indices and carotid intima-media thickness in physically fit adults: CHIEF atherosclerosis study. Endocr Metab Immune Disord Drug Targets 2023.
29.
Arshi B, van den Berge JC, van Dijk B, Deckers JW, Ikram MA, Kavousi M. Implications of the ACC/AHA risk score for prediction of heart failure: the Rotterdam Study. BMC Med. 2021;19(1):43.PubMedPubMedCentral
30.
Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496–509.
31.
Xu L, Wu M, Chen S, Yang Y, Wang Y, Wu S, Tian Y. Triglyceride-glucose index associates with incident heart failure: a cohort study. Diabetes Metab. 2022;48(6):101365.PubMed
32.
Li X, Chan JSK, Guan B, Peng S, Wu X, Lu X, Zhou J, Hui JMH, Lee YHA, Satti DI, et al. Triglyceride-glucose index and the risk of heart failure: evidence from two large cohorts and a mendelian randomization analysis. Cardiovasc Diabetol. 2022;21(1):229.PubMedPubMedCentral
33.
Fan J, Song Y, Chen Y, Hui R, Zhang W. Combined effect of obesity and cardio-metabolic abnormality on the risk of cardiovascular disease: a meta-analysis of prospective cohort studies. Int J Cardiol. 2013;168(5):4761–8.PubMed
34.
Clark AL, Fonarow GC, Horwich TB. Waist circumference, body mass index, and survival in systolic heart failure: the obesity paradox revisited. J Card Fail. 2011;17(5):374–80.PubMed
35.
Rauchhaus M, Coats AJ, Anker SD. The endotoxin-lipoprotein hypothesis. Lancet. 2000;356(9233):930–3.PubMed
36.
Tai S, Fu L, Zhang N, Yang R, Zhou Y, Xing Z, Wang Y, Zhou S. Association of the cumulative triglyceride-glucose index with major adverse cardiovascular events in patients with type 2 diabetes. Cardiovasc Diabetol. 2022;21(1):161.PubMedPubMedCentral
37.
Wang J, Zhang S, Jiao Y, Zheng L, Sun Y, Sun Z. Cumulative exposure to elevated blood pressure better predicts cardiovascular disease risk in rural chinese adults. Front Public Health. 2022;10:1006220.PubMedPubMedCentral
38.
Dai L, Xu J, Zhang Y, Wang A, Chen Z, Mo J, Li H, Meng X, Wu S, Wang Y. Cumulative burden of lipid profiles predict future incidence of ischaemic stroke and residual risk. Stroke Vasc Neurol. 2021;6(4):581–8.PubMedPubMedCentral
39.
Reaven GM. The insulin resistance syndrome. Curr Atheroscler Rep. 2003;5(5):364–71.PubMed
40.
41.
Erqou S, Adler AI, Challa AA, Fonarow GC, Echouffo-Tcheugui JB. Insulin resistance and incident heart failure: a meta-analysis. Eur J Heart Fail. 2022;24(6):1139–41.PubMed
42.
Aroor AR, Mandavia CH, Sowers JR. Insulin resistance and heart failure: molecular mechanisms. Heart Fail Clin. 2012;8(4):609–17.PubMedPubMedCentral
43.
Mordi IR, Lumbers RT, Palmer CNA, Pearson ER, Sattar N, Holmes MV, Lang CC. Type 2 diabetes, metabolic traits, and risk of Heart failure: a mendelian randomization study. Diabetes Care. 2021;44(7):1699–705.PubMedPubMedCentral
44.
Verdecchia P, Reboldi G, Schillaci G, Borgioni C, Ciucci A, Telera MP, Santeusanio F, Porcellati C, Brunetti P. Circulating insulin and insulin growth factor-1 are independent determinants of left ventricular mass and geometry in essential hypertension. Circulation. 1999;100(17):1802–7.PubMed
45.
Pagé A, Dumesnil JG, Clavel MA, Chan KL, Teo KK, Tam JW, Mathieu P, Després JP, Pibarot P. Metabolic syndrome is associated with more pronounced impairment of left ventricle geometry and function in patients with calcific aortic stenosis: a substudy of the ASTRONOMER (aortic stenosis Progression Observation Measuring Effects of Rosuvastatin). J Am Coll Cardiol. 2010;55(17):1867–74.PubMed
46.
Vardeny O, Gupta DK, Claggett B, Burke S, Shah A, Loehr L, Rasmussen-Torvik L, Selvin E, Chang PP, Aguilar D, et al. Insulin resistance and incident heart failure the ARIC study (atherosclerosis risk in Communities). JACC Heart Fail. 2013;1(6):531–6.PubMedPubMedCentral
Metadata
Title
Relationship between cumulative exposure to triglyceride-glucose index and heart failure: a prospective cohort study
Authors
Huancong Zheng
Guanzhi Chen
Kuangyi Wu
Weiqiang Wu
Zegui Huang
Xianxuan Wang
Zekai Chen
Zefeng Cai
Zhiwei Cai
Yulong Lan
Shouling Wu
Youren Chen
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2023
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/s12933-023-01967-5

Other articles of this Issue 1/2023

Cardiovascular Diabetology 1/2023 Go to the issue

Study Protocol

Rationale and design of an investigator-initiated, multicenter, prospective, placebo-controlled, double-blind, randomized trial to evaluate the effects of finerenone on vascular stiffness and cardiorenal biomarkers in type 2 diabetes and chronic kidney disease (FIVE-STAR)

Research

Higher HbA1c variability is associated with increased arterial stiffness in individuals with type 1 diabetes

Research

Acid sphingomyelinase promotes diabetic cardiomyopathy via NADPH oxidase 4 mediated apoptosis

Correction

Correction: CXCL5 suppression recovers neovascularization and accelerates wound healing in diabetes mellitus

Research

Predicting long-term prognosis after percutaneous coronary intervention in patients with new onset ST-elevation myocardial infarction: development and external validation of a nomogram model

Research

High triglyceride-glucose index predicts cardiovascular events in patients with coronary bifurcation lesions: a large-scale cohort study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits